Hospital trade groups have lodged strong objections to CMS's proposal to maintain deep Medicare Part B reimbursement cuts, while PhRMA is suggesting even further 340B reforms.

Hospitals Urge CMS To Abandon Medicare Part B Cuts While PhRMA Presses For More Action

Hospital trade groups are lodging strong objections to maintaining steep cuts in Medicare Part B drug reimbursement as part of the Fiscal Year 2022 final rule for the hospital outpatient prospective payment system (OPPS), while the trade group for brand name pharmaceutical manufacturers is suggesting even further reforms.

The groups’ comments were part of the over 1200 letters that the U.S. Centers for Medicare & Medicaid Services (CMS) received by its September 17th deadline on its proposed rule that takes effect on January 1, 2022.  Hospitals that participate in the 340B program are particularly concerned CMS may keep intact a nearly 30% cut in Medicare Part B reimbursement first enacted in 2018. Since that time, drugs acquired through the 340B program are reimbursed at the average sales price (ASP) minus 22.5%. Prior to 2018, the reimbursement rate was ASP plus 6%.

Hospital trade groups are lodging strong objections to maintaining steep cuts in Medicare Part B reimbursement as part of the Fiscal Year 2022 final rule for the hospital outpatient prospective payment system (OPPS), while the trade group for brand name manufacturers is suggesting even further reimbursement cuts.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report